Scinai Licenses Universal Flu Vaccine Candidate VAA437
Ticker: SCNI · Form: 6-K · Filed: 2024-09-26T00:00:00.000Z
Sentiment: neutral
Topics: licensing-agreement, drug-development, vaccine
TL;DR
Scinai just licensed its universal flu vaccine (VAA437) globally to a US company. Potential future cash!
AI Summary
On September 26, 2024, Scinai Immunotherapeutics Ltd. entered into a license agreement with an unaffiliated U.S. private company. This agreement grants the Licensee exclusive global rights to Scinai's VAA437 (a universal flu vaccine candidate).
Why It Matters
This licensing deal could provide Scinai with future revenue streams and advance the development of its universal flu vaccine candidate.
Risk Assessment
Risk Level: medium — The filing details a licensing agreement, but the financial terms and potential success of the licensed product are not yet fully disclosed, introducing uncertainty.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Registrant and licensor
- VAA437 (drug_candidate) — Licensed universal flu vaccine candidate
- September 26, 2024 (date) — Date of license agreement
FAQ
What are the specific financial terms of the license agreement?
The filing does not disclose the specific financial terms of the license agreement, only that exclusive global rights were granted.
Who is the unaffiliated U.S. private company that entered into the agreement?
The filing refers to the counterparty as an 'unaffiliated U.S. private company' and does not disclose its name.
What is the current development stage of VAA437?
The filing identifies VAA437 as a 'universal flu vaccine candidate' but does not specify its current development stage.
What does 'exclusive global rights' entail for the Licensee?
Exclusive global rights mean the Licensee has the sole right to develop, manufacture, and commercialize VAA437 worldwide.
What is the significance of this filing being a Form 6-K?
A Form 6-K is a report of foreign private issuers that provides information that the company has made or is required to make public in its home country, file with a stock exchange, or distribute to its security holders.
From the Filing
0001213900-24-082106.txt : 20240926 0001213900-24-082106.hdr.sgml : 20240926 20240926124529 ACCESSION NUMBER: 0001213900-24-082106 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240926 FILED AS OF DATE: 20240926 DATE AS OF CHANGE: 20240926 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37353 FILM NUMBER: 241327544 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 6-K 1 ea0215074-6k_scinai.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of September 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Explanatory Note On September 26, 2024, Scinai Immunotherapeutics Ltd. (“Scinai”) entered into a license agreement with an unaffiliated U.S. private company (“Licensee”), pursuant to which Scinai has granted Licensee exclusive global rights to certain patents and know-how under Scinai’s agreement with the Max Planck Society and the University Medical Center Göttingen for the development and commercialization of licensed products in exchange for an up-front license fee payable by the earlier of Licensee’s completion of specified pre-clinical work or December 15, 2024, as well as other contingent development milestone payments across several indications and royalties on net sales of licensed products. This Report on Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-271293 and File No. 333-239344 ) and Form F-3 (File No. 333-274078 and File No. 333-276767 ), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: September 26, 2024 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2